Cephalon Drug Prompts Response in Cancer Study

Biotechnology company Cephalon Inc. said its leukemia drug Treanda, in combination with Genentech Inc.'s Rituxan, prompted a response in non-Hodgkin's lymphoma patients during a midstage study.
Boston.com